Get informed when a big investor buys or sells
+ FollowNovember 3, 2026 - AI Summary
Undervalued by 25.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $45.45 Billion |
|---|---|
| Enterprise Value | $58.35 Billion |
| Earnings per Share | $1.23 |
| Beta | 0.93 |
| Outstanding Shares | 1,166,000,000 |
| P/E Ratio | 98.89 |
|---|---|
| PEG | -214.09 |
| Price to Sales | 2.78 |
| Price to Book Ratio | 6.5 |
| Enterprise Value to Revenue | 3.39 |
| Enterprise Value to EBIT | 46.57 |
| Enterprise Value to Net Income | 115 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 2.13 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products througho...